2,173 results match your criteria Combined B-Cell and T-Cell Disorders

CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.

Clin Adv Hematol Oncol 2022 May;20(5):309-318

Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.

Non-Hodgkin lymphoma (NHL) is the seventh most common type of malignancy worldwide, with approximately 544,000 cases diagnosed in 2020.[1-3] The vast majority of NHLs are derived from B cells. The more than 80 subtypes of B-cell NHL are categorized according to their typical clinical course: indolent or aggressive. Read More

View Article and Full-Text PDF

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report.

Front Oncol 2022 28;12:817969. Epub 2022 Apr 28.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China.

Background: Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive, large B-cell non-Hodgkin's lymphoma. The prognosis of IVLBCL in patients with central nervous system recurrence after first-line chemotherapy treatment is extremely poor. Among immunotherapies, chimeric antigen receptor (CAR) T-cell immunotherapy has been recently found to be a highly effective treatment for B-cell lymphoma, especially for relapsed or refractory diffuse large B-cell lymphoma. Read More

View Article and Full-Text PDF

New Directions for Mantle Cell Lymphoma in 2022.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-15

Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia.

Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International Prognostic Index clinical factors. Read More

View Article and Full-Text PDF

Unity brings strength: Combination of CAR-T cell therapy and HSCT.

Cancer Lett 2022 May 7:215721. Epub 2022 May 7.

Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China. Electronic address:

With the rapid revolution of therapies, hemopoietic stem cell transplantation (HSCT) has become a widely promoted treatment for hematological malignancies. High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation is a standard procedure for patients with primary relapse B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), and allogeneic HSCT is one of the few treatments for patients with acute leukemia. However, refractory and recurrent disease has a negative impact on disease-free survival (DFS) for patients after HSCT. Read More

View Article and Full-Text PDF

Scales of Magt1 Gene: Novel Mutations, Different Presentations.

Iran J Allergy Asthma Immunol 2022 Feb 6;21(1):92-97. Epub 2022 Feb 6.

Department of Pediatric, Immunology and Allergy and Hematopoietic Stem Cell Transplantation Unit, School of Medicine, Ankara University, Ankara, Turkey.

Loss-of-function mutations in magnesium transporter 1 (MAGT1) gene cause X-linked magnesium deficiency with Epstein-Barr virus (EBV) infection and neoplasm (X-MEN), a disease with quite diverse clinical and immunological consequences. The phenotypic characteristics of the initially described patients included CD4+ T cell lymphopenia, immune deficiency, EBV viremia, and EBV-related lymphoproliferative disease. To date, a total of 25 patients have been reported. Read More

View Article and Full-Text PDF
February 2022

Revealing Potential Diagnostic Gene Biomarkers Associated with Immune Infiltration in Patients with Renal Fibrosis Based on Machine Learning Analysis.

J Immunol Res 2022 20;2022:3027200. Epub 2022 Apr 20.

Department of Urology, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu 322000, China.

Chronic kidney disease is characterized by the development of renal fibrosis. The basic mechanisms of renal fibrosis have not yet been fully investigated despite significant progress in understanding the etiology of the disease. In this work, the researchers sought to identify potential diagnostic indicators for renal fibrosis. Read More

View Article and Full-Text PDF

Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

J Immunol 2022 May 27;208(10):2403-2424. Epub 2022 Apr 27.

Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA; and

Lupus susceptibility results from the combined effects of numerous genetic loci, but the contribution of these loci to disease pathogenesis has been difficult to study due to the large cellular heterogeneity of the autoimmune immune response. We performed single-cell RNA, BCR, and TCR sequencing of splenocytes from mice with multiple polymorphic lupus susceptibility loci. We not only observed lymphocyte and myeloid expansion, but we also characterized changes in subset frequencies and gene expression, such as decreased CD8 and marginal zone B cells and increased - and -expressing macrophages. Read More

View Article and Full-Text PDF

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.

Mediterr J Hematol Infect Dis 2022 1;14(1):e2022018. Epub 2022 Mar 1.

Department of Hematology and Oncology, Ascension St. John Hospital.

In the modern era, classification of neoplasms not only depends on immunomorphological features but also on specific disease-defining genetic events. Translocations/rearrangements of MYC/8q24 locus combined with BCL-2 or BCL6 translocations (double/triple hit) are considered hallmarks of high-grade B-cell lymphoma (HGBL), a type of aggressive mature B-cell lymphoma. When cases with immature immunophenotypes present these rearrangements, diagnosis becomes very difficult. Read More

View Article and Full-Text PDF

Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.

Immunotherapy 2022 Jun 20;14(8):599-607. Epub 2022 Apr 20.

Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 201508, China.

Although there is a high curability rate with rituximab chemotherapy, approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) develop disease relapse or primary-refractory lymphoma. The prognosis of HIV+ DLBCL patients is even worse with limited therapeutic options. The case is presented of a 28-year-old man who was diagnosed with HIV-DLBCL, refractory to rituximab-based chemo-immunotherapies and radiotherapy before and maintained a pathologically complete regression with the infusion of haplotype-matched invariant NK T cells and anti-CD20 antibody. Read More

View Article and Full-Text PDF

Clinicopathological Profile and 2 Year Relapse Rates of Non-Hodgkin's Lymphoma in Tertiary Care Center.

J Assoc Physicians India 2022 Apr;70(4):11-12

Army Hospital Research and Referral, New Delhi.

The aim and objectives are to study clinicopathological profiles and 2-year relapse rates of Non-Hodgkin lymphoma,Material :This prospective observational study was conducted from Jan 2017 to May 2021. All newly diagnosed patients of NHL were enrolled and received a CHOP±R regimen for 6 cycles as per B-cell or T-cell lineage. The data was and analyzed using spss software. Read More

View Article and Full-Text PDF

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.

Front Immunol 2022 1;13:858021. Epub 2022 Apr 1.

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Anti-CD30 CAR-T is a potent candidate therapy for relapsed/refractory (r/r) CD30+ lymphomas with therapy limitations, and the efficacy needed to be further improved. Herein a multi-center phase II clinical trial (NCT03196830) of anti-CD30 CAR-T treatment combined with PD-1 inhibitor in r/r CD30+ lymphoma was conducted. After a lymphocyte-depleting chemotherapy with fludarabine and cyclophosphamide, 4 patients in cohort 1 and 3 patients in cohort 2 received 10/kg and 10/kg CAR-T cells, respectively, and 5 patients in cohort 3 received 10/kg CAR-T cells combined with anti-PD-1 antibody. Read More

View Article and Full-Text PDF

Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.

Value Health 2022 Mar 24. Epub 2022 Mar 24.

Novartis Pharmaceuticals, Basel, Switzerland.

Objectives: This study aimed to quantify the value of reducing chimeric antigen receptor T-cell (CAR-T) treatment wait times on patients with refractory and relapsed aggressive blood cancer who can newly gain access to treatment or access treatment earlier in their disease course.

Methods: Using data from the JULIET clinical trial, we first identified the number of additional patients with diffuse large B-cell lymphoma that would have been treated with tisagenlecleucel CAR-T therapy if wait times were shortened. For these patients, we estimated mortality benefits using literature estimates of CAR-T effectiveness. Read More

View Article and Full-Text PDF

Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Front Immunol 2022 4;13:841470. Epub 2022 Mar 4.

Hospices Civils de Lyon, Department of clinical Hematology, Lyon Sud hospital, Pierre-Bénite, France.

Class I Human Leukocyte Antigen (HLA) evolutionary divergence (HED) is a metric which reflects immunopeptidome diversity and has been associated with immune checkpoint inhibitor responses in solid tumors. Its impact and interest in allogeneic hematopoietic stem cell transplantation (HCT) have not yet been thoroughly studied. This study analyzed the clinical and immune impact of class I and II HED in 492 acute myeloid leukemia (AML) recipients undergoing HCT. Read More

View Article and Full-Text PDF

A candidate multi-epitope vaccine against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae induces robust humoral and cellular response in mice.

Vaccine 2022 Apr 17;40(16):2370-2378. Epub 2022 Mar 17.

College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, Hebei, China. Electronic address:

Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Read More

View Article and Full-Text PDF

A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.

Front Immunol 2022 28;13:781364. Epub 2022 Feb 28.

Department of Immunology, Medical University of Warsaw, Warsaw, Poland.

Regulatory T cells (Tregs) are capable of inhibiting the proliferation, activation and function of T cells and play an important role in impeding the immune response to cancer. In chronic lymphocytic leukemia (CLL) a dysfunctional immune response and elevated percentage of effector-like phenotype Tregs have been described. In this study, using the Eµ-TCL1 mouse model of CLL, we evaluated the changes in the Tregs phenotype and their expansion at different stages of leukemia progression. Read More

View Article and Full-Text PDF

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.

J Immunother Cancer 2022 Mar;10(3)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Background: T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell therapy. Allogeneic natural killer (NK) cells have demonstrated efficacy and safety against malignancies without inducing graft-versus-host-disease, highlighting the feasibility for an 'off the shelf' cellular therapeutic. Read More

View Article and Full-Text PDF

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.

Blood Adv 2022 May;6(9):2757-2762

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Polatuzumab vedotin (PV) is an antibody-drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included in the registration study, and reports of PV use after CAR T cells are limited. This multicenter retrospective analysis included patients with LBCL who relapsed or progressed after CAR T-cell therapy and subsequently received PV with or without rituximab and bendamustine between July 2019 and May 2021. Read More

View Article and Full-Text PDF

NSG-Mice Reveal the Importance of a Functional Innate and Adaptive Immune Response to Overcome RVFV Infection.

Viruses 2022 02 8;14(2). Epub 2022 Feb 8.

Institute of Veterinary-Pathology, Faculty of Veterinary Medicine, Leipzig University, 04103 Leipzig, Germany.

Rift Valley fever (RVF) is a zoonotic disease caused by RVF Phlebovirus (RVFV). The RVFV MP-12 vaccine strain is known to exhibit residual virulence in the case of a deficient interferon type 1 response. The hypothesis of this study is that virus replication and severity of lesions induced by the MP-12 strain in immunocompromised mice depend on the specific function of the disturbed pathway. Read More

View Article and Full-Text PDF
February 2022

Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.

Cancer 2022 May 24;128(9):1863-1870. Epub 2022 Feb 24.

Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.

Background: Boys with acute lymphoblastic leukemia (ALL) have historically experienced inferior survival compared to girls. This study determined whether sex-based disparities persist with contemporary therapy and whether patterns of treatment failure vary by sex.

Methods: Patients 1 to 30. Read More

View Article and Full-Text PDF

Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.

Int Immunopharmacol 2022 May 18;106:108630. Epub 2022 Feb 18.

Department of Pathology, Fourth Medical Center, Chinese PLA General Hospital, Beijing 100048, China. Electronic address:

This study evaluated the basic immune status of cervical cancer and the influences of immunotherapy on the immune microenvironment, and analyzed the correlation between changes in the immune microenvironment and prognosis. We retrospectively analyzed the treatment status of 8 patients with advanced recurrent cervical cancer treated with PD-1 inhibitors and detected the tumor-infiltrating immune markers (CD3, CD4, CD8, CD20, CD56, CD68, PD-1, and PD-L1) by immunohistochemistry. All patients showed good tolerance during the treatment. Read More

View Article and Full-Text PDF

T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis.

Cancers (Basel) 2022 Jan 25;14(3). Epub 2022 Jan 25.

Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic.

In this retrospective study on 67 patients with hepatocellular carcinoma (HCC), after tumor resection, we evaluated the significance of CD3+ and CD8+ T-lymphocytes and CD20+ B-lymphocytes in tumor and non-tumor liver for time to recurrence (TTR), disease-free survival (DFS) and overall survival. After immunohistochemical staining, the density of nucleated lymphocyte profiles (Q) was estimated stereologically in the tumor center (TC), inner margin (inn M), outer margin (out M), peritumor and non-tumor liver. In TC, intermediate and high Q of CD8+ cells predicted longer TTR, whereas CD3+ and CD20+ were predictive only at high Q. Read More

View Article and Full-Text PDF
January 2022

Primary Adrenal Lymphoma: Two Case Series From China.

Front Endocrinol (Lausanne) 2021 28;12:778984. Epub 2022 Jan 28.

Department of Endocrinology, Hainan Branch of People's Liberation Army (PLA) General Hospital, Sanya, China.

Objective: Primary adrenal lymphoma (PAL) is a rare form of adrenal mass. We summarize our experience in its clinical presentation, biochemical indexes, radiological features, pathological information, therapy regimens, and outcomes.

Methods: This was an institutional review board-approved retrospective review of medical records and surgical pathology specimens of patients with a diagnosis of PAL at the Chinese People's Liberation Army General Hospital and the First Affiliate Hospital of Xiamen University between July 2007 and July 2017. Read More

View Article and Full-Text PDF

An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.

Cell 2022 02 10;185(4):614-629.e21. Epub 2022 Feb 10.

Harvard Medical School, Boston, MA, USA; Boston Children's Hospital, Precision Vaccines Program, Boston, MA, USA; Broad Institute of MIT & Harvard, Cambridge, MA, USA.

Activation of the innate immune system via pattern recognition receptors (PRRs) is key to generate lasting adaptive immunity. PRRs detect unique chemical patterns associated with invading microorganisms, but whether and how the physical properties of PRR ligands influence the development of the immune response remains unknown. Through the study of fungal mannans, we show that the physical form of PRR ligands dictates the immune response. Read More

View Article and Full-Text PDF
February 2022

Primary T-Cell Lymphoma of the Parotid Gland.

J Coll Physicians Surg Pak 2022 Mar;32(3):392-394

Department of Pathology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey.

Primary malignant lymphomas of parotid gland are very rare. Most are B-cell lymphomas, and T-cell lymphomas are very rare. Unfortunately, fine needle aspiration biopsy is non-diagnostic. Read More

View Article and Full-Text PDF

Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.

Adv Clin Exp Med 2022 Mar;31(3):327-335

Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, China.

Background: A patient with relapsed mantle cell lymphoma (MCL) showed stable disease after receiving ibrutinib therapy as a salvage therapy, after the failure of his first chimeric antigen receptor (CAR)-T 19 cell therapy.

Objectives: The combined effects of CAR-T 19 cells from the patient and ibrutinib on JeKo-1 cell were explored in vitro and in vivo.

Material And Methods: The expression of programmed death-1 (PD-1) receptor on CD3+ T cells in the peripheral blood decreased from 82. Read More

View Article and Full-Text PDF

Unusual primary central nervous system T-cell/histiocyte-rich large B-cell lymphoma: a case report.

BMJ Case Rep 2022 Feb 8;15(2). Epub 2022 Feb 8.

Neurology, Fundacion Santa Fe de Bogota, Bogotá, Colombia.

We report the case of a 54-year-old immunocompetent woman who presented with a primary T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL) of the central nervous system without systemic involvement, diagnosed by means of a brain biopsy. She was treated with corticosteroids and we subsequently started chemotherapy with rituximab, methotrexate, ifosfamide and intrathecal cytarabine. The patient's symptoms gradually improved over the first weeks and we followed-up with autologous haematopoietic cell transplantation. Read More

View Article and Full-Text PDF
February 2022

[Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2022 Feb;30(1):126-130

Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China,E-mail:

Objective: To analyze the clinical characteristics and long-term prognosis of patients with primary bone lymphoma (PBL).

Methods: The clinical data of 21 patients with PBL treated in our center from 2005 to 2018 were analyzed retrospectively, the clinical characteristics and the factors affecting prognosis of the patients were analyzed.

Results: The median age of all the 21 newly diagnosed PBL patients was 40(12-71) years old. Read More

View Article and Full-Text PDF
February 2022

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.

Front Immunol 2021 14;12:808964. Epub 2022 Jan 14.

Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.

The clinical success of immunotherapy has revolutionized the treatment of cancer patients, bringing renewed attention to tumor-infiltrating lymphocytes (TILs) of various cancer types. Immune checkpoint blockade is effective in patients with mismatched repair defects and high microsatellite instability (dMMR-MSI-H) in metastatic colorectal cancer (CRC), leading the FDA to accelerate the approval of two programmed cell death 1 (PD-1) blocking antibodies, pembrolizumab and nivolumab, for treatment of dMMR-MSI-H cancers. In contrast, patients with proficient mismatch repair and low levels of microsatellite stability or microsatellite instability (pMMR-MSI-L/MSS) typically have low tumor-infiltrating lymphocytes and have shown unsatisfied responses to the immune checkpoint inhibitor. Read More

View Article and Full-Text PDF
February 2022

Cytometric analysis and clinical features in a Moroccan cohort with severe combined immunodeficiency.

Hum Antibodies 2022 Jan 21. Epub 2022 Jan 21.

Laboratory of Cellular Immunology, National Institute of Hygiene, Rabat, Morocco.

Severe combined immunodeficiency (SCID) is a form of primary immunodeficiency disease (PID). It is characterized by a serious abnormality of the cellular and sometimes humoral system due to a deficiency in development of T cells, B cells and/or NK cells. The early diagnosis of SCID improves the prognosis. Read More

View Article and Full-Text PDF
January 2022

Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.

Med Oncol 2022 Jan 29;39(4):44. Epub 2022 Jan 29.

Department of Blood Transfusion, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL). The R-CHOP immunochemotherapy regimen is the first-line treatment option for DLBCL patients and has greatly improved the prognosis of DLBCL, making it a curable disease. However, drug resistance or relapse is the main challenge for current DLBCL treatment. Read More

View Article and Full-Text PDF
January 2022